why choose us

Clinical Trials Search

Showing 9,050 of 132,656 result(s)
A Multicenter Controlled Study to Evaluate Efficacy and Safety of Focused Ultrasound Device (FUBA5200) for Noninvasive Fat Reduction

Status: Completed

Condition: Body Sculpting

Interventions: the Focused Ultrasound Fat Reduction device (FUBA5200) is manufactured by Shanghai Carnation Medical Technology Co., Ltd

Date: 2023-08-21

Attention Bias Modification Training for Social Phobia (ABMSP)

Status: Completed

Condition: Social Anxiety Disorder

Interventions: The ABMT is aimed to modify attentional bias for negative stimuli in social anxiety by deliberately inducing the participant's attention to posit

Date: 2023-08-21

Protocol to Support Breastfeeding for Postpartum Women and Mothers of Babies With Congenital Heart Disease

Status: Completed

Condition: Breastfeeding

Interventions:

Over the 6 months of the intervention, 1 video per month was sent, a total of 6 videos, via the mobile application, with guidance on breastfeeding:

Date: 2023-08-21

Validity and Reliability of the Turkish Version of the Post-Stroke Physical Activity Barriers Scale in Patients With Stroke

Status: Completed

Condition: Stroke

Interventions: Participants will only be asked to fill out the questionnaires.

Date: 2023-08-21

Performance and Safety of the Lipo-transfer Cannulas in Patients Underlying Lipofilling Treatment

Status: COMPLETED

Condition: Lipodystrophy

Interventions:

Date: 2023-08-21

Effect of Whey Protein Supplementation on Postoperative Outcomes After Gynecological Cancer Surgery

Status: COMPLETED

Condition: Whey Protein

Interventions: Participants are given Isolated whey protein supplement in evening before surgery and first day of post operation to compare with standard operative c

Date: 2023-08-21

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

Status: COMPLETED

Condition: Chronic Plaque Psoriasis

Interventions: Study participants will receive placebo subcutaneously at pre-specified time points in the placebo arm as comparator and in the bimekizumab arm to mai

Date: 2023-08-21

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Status: COMPLETED

Condition: Solid Tumor

Interventions: IV infusion

Date: 2023-08-21

Joint Inflation With Nominal-pressure and Stability Approach in DES Optimization

Status: COMPLETED

Condition: Acute Coronary Syndrome

Interventions: OCT- or IVUS-guided JINS approach in DES implantation (DES types including Healing-Targeted SUPREME;Infinity Sirolimus-Eluting Stent, GuReater™ S

Date: 2023-08-21

The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction

Status: COMPLETED

Condition: Dermal Hypersensitivity Reaction

Interventions:

Patients will start by getting dupilumab 600 milligram (mg) subcutaneously at week 0, followed by 300 mg every 2 weeks starting at week 2. The last

Date: 2023-08-21